Sprint Bioscience AB (SPRINT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sprint Bioscience AB (SPRINT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8259
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sprint Bioscience AB (Sprint Bioscience) is a developer of pharmaceutical products in the areas of cancer and metabolism. The company develops STK25, a drug candidate against a new target protein for the treatment of type 2 diabetes; VPS34, a drug candidate for the treatment of various types of cancer; and PIP4K2A, a drug candidate for the treatment of cancer. Sprint Bioscience builds drug discovery pipeline of innovative targets within oncology. The company conducts research on various products for the treatment of tumor metabolism and diabetes. It out-license its projects to pharmaceutical companies that brings them to the clinic and market. The company collaborates with universities and individual researchers. Sprint Bioscience is headquartered in Stockholm, Sweden.

Sprint Bioscience AB (SPRINT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sprint Bioscience AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Sprint Bioscience Raises Funds Through Venture Financing 10
Partnerships 11
Sprint Bioscience Enters into Research Agreement with Karolinska Institutet 11
Sprint Bioscience Enters into Co-Development Agreement with University of Gothenburg 12
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 13
Licensing Agreements 14
Petra Pharma Enters into Licensing Agreement with Sprint Bioscience 14
Bayer HealthCare Enters into Licensing agreement with Sprint Bioscience 15
Sprint Bioscience Enters into Licensing Agreement with Bayer HealthCare 16
Equity Offering 17
Sprint Bioscience to Raise USD2.3 Million in Private Placement of Shares 17
Sprint Bioscience Raises USD3 Million in IPO 18
Sprint Bioscience AB – Key Competitors 19
Sprint Bioscience AB – Key Employees 20
Sprint Bioscience AB – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Product News 22
Jul 10, 2018: Sprint Bioscience Strengthens the Vps34 Project by Patenting the use of Newly Developed Biomarkers in Immune-oncology 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sprint Bioscience AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sprint Bioscience AB, Deals By Therapy Area, 2012 to YTD 2018 8
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sprint Bioscience Raises Funds Through Venture Financing 10
Sprint Bioscience Enters into Research Agreement with Karolinska Institutet 11
Sprint Bioscience Enters into Co-Development Agreement with University of Gothenburg 12
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 13
Petra Pharma Enters into Licensing Agreement with Sprint Bioscience 14
Bayer HealthCare Enters into Licensing agreement with Sprint Bioscience 15
Sprint Bioscience Enters into Licensing Agreement with Bayer HealthCare 16
Sprint Bioscience to Raise USD2.3 Million in Private Placement of Shares 17
Sprint Bioscience Raises USD3 Million in IPO 18
Sprint Bioscience AB, Key Competitors 19
Sprint Bioscience AB, Key Employees 20

List of Figures
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sprint Bioscience AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sprint Bioscience AB (SPRINT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LumiraDx Ltd (LMDX):企業の財務・戦略的SWOT分析
    LumiraDx Ltd (LMDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Compal Electronics, Inc.:企業の戦略・SWOT・財務分析
    Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bharti Infratel Ltd
    Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Rizzani De Eccher S.P.A.
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cisco Systems, Inc (CSCO)-エネルギー分野:企業M&A・提携分析
    Summary Cisco Systems, Inc (Cisco) is a technology services provider, which designs, manufactures and sells Internet protocol (IP)-based networking systems and other products. The company’s products include blade switches, analytics and automation software, application networking services, interface …
  • ConAgra Foods Inc:戦略・SWOT・企業財務分析
    ConAgra Foods Inc - Strategy, SWOT and Corporate Finance Report Summary ConAgra Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Devoteam Sa
    Devoteam Sa - Strategy, SWOT and Corporate Finance Report Summary Devoteam Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ImaginAb Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ImaginAb Inc (ImaginAb) is an immune and oncology imaging company that develops in vivo antibody-based imaging agents. It is engaged in the discovery, development, and production of new compounds and products in human health and cosmetics, agriculture and food sectors. The company’s product …
  • Cermaq Group AS:企業の戦略的SWOT分析
    Cermaq Group AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • ZIOPHARM Oncology Inc (ZIOP)-製薬・医療分野:企業M&A・提携分析
    Summary Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc is a biotechnology company that discovers and develops cancer therapies. The company develops novel gene expression, control and cell technologies to provides cell-based therapies for the treatment of cancer and graft-versus-host-disease …
  • Sterling Bank Plc
    Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Southern Maryland Electric Cooperative Inc:発電所・企業SWOT分析
    Southern Maryland Electric Cooperative Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, infor …
  • Bellicum Pharmaceuticals Inc (BLCM):企業の財務・戦略的SWOT分析
    Summary Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical stage biopharmaceutical company, which is engaged in developing cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the …
  • Curida AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Curida AS (Curida) is a contract development and manufacturing organization that manufactures sterile liquid pharmaceuticals based on unit-dose Blow-Fill-Seal (BFS) technology. It specializes in the development of nasal and inhalation drug products. The company provides laboratory, analytica …
  • HD Supply Inc:企業の戦略的SWOT分析
    HD Supply Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Damac Real Estate Development Ltd:企業の戦略・SWOT・財務分析
    Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report Summary Damac Real Estate Development Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Golden Dawn Minerals Inc (GOM):企業の財務・戦略的SWOT分析
    Summary Golden Dawn Minerals Inc (Golden Dawn) is a mining and mineral exploration and development company. it offers acquisition, exploration, operations, management, production, and development of gold, uranium, silver, iron, lead, zinc, base metals, precious metals, and mineral resource deposit p …
  • Brasfield & Gorrie LLC:企業の戦略・SWOT・財務分析
    Brasfield & Gorrie LLC - Strategy, SWOT and Corporate Finance Report Summary Brasfield & Gorrie LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Toromont Industries Ltd:企業の戦略・SWOT・財務情報
    Toromont Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Toromont Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Urstadt Biddle Properties Inc:企業の戦略・SWOT・財務情報
    Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆